Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 31, 2007 Brian Lawler	Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division.
The Motley Fool February 8, 2008 Brian Lawler	Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses.
The Motley Fool February 28, 2008 Brian Lawler	Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful.
The Motley Fool April 16, 2008 Brian Lawler	Alpharma's Soothing Guidance Alpharma lowers its financial guidance for 2008. Investors, take note.
The Motley Fool December 13, 2007 Brian Lawler	Alpharma Gives to Get The generics drugmaker forecasts its 2008 financials, with guidance of expenses up and income down.
The Motley Fool August 25, 2008 Brian Lawler	King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market.
The Motley Fool February 25, 2008 Brian Lawler	The Yin and Yang of Endo Endo Pharmaceuticals' fiscal 2007 report offered positive year-end financial results and a little bit of balance-sheet sourness.
The Motley Fool September 12, 2008 Brian Lawler	King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool March 1, 2007 Brian Lawler	King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool April 2, 2007 Brian Lawler	Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.
The Motley Fool January 15, 2008 Brian Orelli	Fewer Generics in Fido's Future TEVA considers selling its small animal-health business.
The Motley Fool May 18, 2010 Brian Orelli	What Astellas' Purchase of OSI Means for Biotech Investors Stop buying for the potential takeout.
The Motley Fool August 22, 2007 Brian Orelli	Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note.
The Motley Fool September 29, 2006 Brian Lawler	Alpharma's Painless Results A new addition to an already successful drug promises good results for investors.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
Chemistry World July 1, 2013 Laura Howes	Aspen in $1 billion deal with Merck The deal involves 11 of Merck's drug brands and an active pharmaceutical ingredient business in the Netherlands.
The Motley Fool December 7, 2007 Brian Lawler	Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool November 5, 2007 Brian Lawler	King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
Chemistry World June 24, 2011 Hepeng Jia	Pharma pollution is out of control in China Active pharmaceutical ingredients pollution problems seem to continue even after the Chinese government increased efforts to reduce environmental pollution from drug makers.
The Motley Fool May 5, 2008 Brian Lawler	Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week.
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool March 3, 2009 Robert Steyer	Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company.
The Motley Fool August 14, 2008 Brian Lawler	A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
The Motley Fool October 5, 2007 Brian Lawler	OxyContin in the Crosshairs Again The state of Kentucky sues Purdue Frederick over the monetary burden that abusers of the drug OxyContin place on counties within the state.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
The Motley Fool December 11, 2008 Brian Orelli	A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone.
Managed Care August 2004	MCOs, Drug Manufacturers Have Lots of PR Work to Do Managed care companies, and pharmaceuticals especially, receive disheartening numbers in a consumer satisfaction poll.
Pharmaceutical Executive October 1, 2011	Pharma Futures: The Next 30 Years Success for the next 30 years in the pharmaceutical industry depends significantly on navigating the myths and mental traps of emerging market strategy.
The Motley Fool July 24, 2007 Brian Lawler	Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Bio-IT World July 15, 2003	Solutia Streamlines Route from Lab to Production Solutia Pharmaceutical Services, under pressure to control costs, built a single, integrated software application that enables management and control of every resource used in the development and manufacture of API (active pharmaceutical ingredient) products.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
The Motley Fool July 25, 2011	West Pharmaceutical Services Earnings Preview West Pharmaceutical Services will unveil its latest earnings on Thursday, July 28.